Oncomine™ BRCA Assay GX (Ion Torrent™)

The Oncomine BRCA Assay GX is a targeted next-generation sequencing (NGS) assay designed to provide comprehensive amplification of all coding regions of the human BRCA1 and BRCA2 genes, enabling accurate and sensitive detection of various mutation classes. This assay is part of a comprehensive workflow on the Ion Torrent Genexus System. It is optimized for sequencing on the Genexus Integrated Sequencer using the GX5 Chip. The Genexus Integrated Sequencer performs library preparation, sequencing, analysis, and reporting in an automated workflow. When used in conjunction with the Genexus Purification System, it delivers an end-to-end workflow from biological specimen all the way to the report in a single day.

Features of the Oncomine BRCA Assay GX include:
• Optimized primer design and amplification chemistry enable highly specific target enrichment
• Detects SNVs, InDels, and large genomic rearrangements (LGR), including exon-level and gene-level deletions or duplications
• Compatible with as little as 10 ng input DNA from FFPE tissue or whole blood samples
• Sequence up to16 samples on a single lane of a GX5 Chip
• Compatible with the Genexus FFPE DNA/RNA Purification Kit and Genexus Multisample DNA Purification Kit for an end-to-end workflow from biological specimen to the final report

The assay kit includes two DNA pools of Ion AmpliSeq oligonucleotide primers and Genexus Strips 1 & 2-AS library reagents, enough to sequence up to 32 samples on the Genexus Integrated Sequencer. One sequencing run uses one lane on the GX5 Chip and accommodates up to sixteen samples. Additional Genexus sequencer reagents and supplies must be ordered separately.

The BRCA1 and BRCA2 genes are tumor suppressor genes that code for proteins that are vital components of the homologous recombination pathway of DNA damage repair. BRCA mutations resulting in the deficiency of either gene have been shown to result in inefficient activation of this function and are linked to hereditary predisposition to cancer. Errors in the coding sequence of BRCA genes have been detected in germline and somatic mutations and also occur in tumor samples.